Juvenile Huntington disease exacerbated by methylphenidate: Case report

Journal of Child Neurology

Volumn 23, Issue 7, 2008, Pages 807-809

  Waugh, Jeff L ^a   Miller, Van S ^b   Chudnow, Robert S ^b   Dowling, Michael Morgan ^c  

^a CHILDREN S MEDICAL CENTER   (United States)

^b LLP   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Attention deficit; Basal ganglia; Huntington disease

Indexed keywords

ADENOSINE; CYTOSINE; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CAUDATE NUCLEUS; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; DYSARTHRIA; DYSTONIA; FAMILY HISTORY; GENETIC ANALYSIS; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RESPIRATORY DISTRESS; RIGIDITY; SCHOOL CHILD; TREMOR; WALKING DIFFICULTY;

AGE OF ONSET; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DNA REPEAT EXPANSION; DOPAMINE UPTAKE INHIBITORS; HUMANS; HUNTINGTON DISEASE; MALE; METHYLPHENIDATE;

EID: 47349132531     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808314152     Document Type: Article

References (19)

1. Wexler NS, Lorimer J., Porter J., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A. 2004; 101:3498-3503.
2. Gonzalez-Alegre P., Afifi AK Clinical characteristics of childhood-onset (juvenile) Huntington disease: Report of 12 patients and review of the literature. J Child Neurol. 2006; 21:223-229.
3. Rasmussen A., Macias R., Yescas P., et al. Huntington disease in children: Genotype-phenotype correlation. Neuropediatrics. 2000; 31:190-194.
4. Yoon G., Kramer J., Zanko A., et al. Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology. 2006; 67:1265-1267.
5. Siesling S., Vegter-van der Vlis M., Roos RA Juvenile Huntington disease in the Netherlands. Pediatr Neurol. 1997; 17:37-43.
6. Seneca S., Fagnart D., Keymolen K., et al. Early onset Huntington disease: A neuronal degeneration syndrome. Eur J Pediatr. 2004; 163:717-721.
7. Jardri R., Medjkane F., Cuisset JM, et al. Huntington's disease presenting as a depressive disorder with psychotic features. J Am Acad Child Adolesc Psychiatry. 2007; 46:307-308.
8. Andrew SE, Goldberg YP, Kremer B., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993; 4:398-403.
9. Langbehn DR, Brinkman RR, Falush D., et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65:267-277.
10. Rosenblatt A., Brinkman RR, Liang KY, et al. Familial influence on age of onset among siblings with Huntington disease. Am J Med Genet. 2001; 105:399-403.
11. Foroud T., Gray J., Ivashina J., et al. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999; 66:52-56.
12. Rosenblatt A., Liang KY, Zhou H., et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology. 2006; 66:1016-1020.
13. Squitieri F., Ciarmiello A., Di Donato S., et al. The search for cerebral biomarkers of Huntington's disease: A review of genetic models of age at onset prediction. Eur J Neurol. 2006; 13:408-415.
14. Li JL, Hayden MR, Warby SC, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: The HD MAPS study. BMC Med Genet. 2006; 7: 71.
15. Efron D., Jarman F., Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics. 1997; 100:662-666.
16. Yuan J., McCann U., Ricaurte G. Methylphenidate and brain dopamine neurotoxicity. Brain Res. 1997; 767:172-175.
17. Cyr M., Sotnikova TD, Gainetdinov RR, et al. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J. 2006; 20:2541-2543.
18. Klawans HL, Goetz CG, Paulson GW, et al. Levodopa and presymptomatic detection of Huntington's disease-eight-year follow-up. N Engl J Med. 1980; 302:1090.
19. Gay CT, Ryan SG Paroxysmal kinesigenic dystonia after methylphenidate administration. J Child Neurol. 1994; 9:45-46.